<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379795</url>
  </required_header>
  <id_info>
    <org_study_id>FVF3426g (Cohort 1)</org_study_id>
    <nct_id>NCT00379795</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO</brief_title>
  <official_title>An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This was an open-label, multicenter, extension study of intravitreally administered
      ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary
      or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration
      (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g
      (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort enrolled
      patients with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the
      6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored
      study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). The results of the second cohort
      are reported separately (NCT01442064). The first cohort of this study enrolled two subsets of
      patients: ranibizumab experienced and ranibizumab-naive. Patients were enrolled within 14
      days of completion of the 24 month treatment phase of the previous study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Ocular Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye).
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Non-ocular Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Additional information about adverse events can be found in the adverse events section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters</measure>
    <time_frame>Extension study baseline, Months 3, 6, 9, 12, 15, 18, 21 and 24</time_frame>
    <description>Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters</measure>
    <time_frame>Extension study baseline, Months 12 and 24</time_frame>
    <description>Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">853</enrollment>
  <condition>Choroidal Neovascularization, Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumad 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5 mg</intervention_name>
    <description>Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)</description>
    <arm_group_label>Ranibizumad 0.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Completion of the treatment phase (through Month 24) of a Genentech-sponsored
             ranibizumab study for AMD (FVF2598g, FVF2587g, or FVF2428g) (Cohort 1)

          -  Expectation by the investigator that the subject may potentially benefit from
             intravitreal anti-vascular endothelial growth factor (VEGF) treatment

        Exclusion Criteria:

          -  Previous subfoveal focal laser photocoagulation in the study eye

          -  Previous pegaptanib sodium injection in the study eye

          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month
             preceding Day 0 of this extension study

          -  History of submacular surgery or other surgical intervention for AMD in the study eye

          -  History of glaucoma filtering surgery in the study eye

          -  History of corneal transplant in the study eye

          -  Concurrent use of systemic anti-EGF agents

          -  Use of AMD treatments not approved by the FDA

          -  Use of intravitreal Avastin(R) (bevacizumab) in the study eye and/or fellow eye

          -  CNV in either eye due to other causes than AMD, such as ocular histoplasmosis, trauma,
             or pathologic myopia for Cohort 1

          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the
             study eye

          -  History of idiopathic or autoimmune-associated uveitis in either eye

          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure â‰¥ 30 mmHg
             despite treatment with antiglaucoma medication)

          -  Pregnancy or lactation

          -  Premenopausal women not using adequate contraception

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use an investigational drug or that might affect interpretation of
             the results of the study or render the subject at high risk for treatment
             complications

          -  Current treatment for active systemic infection

          -  Inability to comply with study or follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Tuomi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <results_first_submitted>April 1, 2011</results_first_submitted>
  <results_first_submitted_qc>December 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2012</results_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNV</keyword>
  <keyword>Lucentis</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>RVO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is an open label multicenter extension study for participants who have completed one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823). Cohort 1 includes patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).</recruitment_details>
      <pre_assignment_details>Participants were classified according to ranibizumab exposure in the previous study and in the extension study. 63 participants (Untreated Group) did not receive study drug in this extension study or in the previous studies and are not included in the safety analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RanibizumabTreated Initial Mono</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Participants in this group received ranibizumab monotherapy (Mono) in previous studies, that is, ranibizumab alone in study FVF2598g or ranibizumab in combination with sham photodynamic therapy (PDT) in study FVF2587g.</description>
        </group>
        <group group_id="P2">
          <title>RanibizumabTreated Initial + PDT</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. This group includes participants who received ranibizumab in combination with photodynamic therapy in Study FVF2428g</description>
        </group>
        <group group_id="P3">
          <title>RanibizumabTreated Sham XO</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated Sham Crossover (XO) includes participants who received sham intravitreal injections before crossing over to receive ranibizumab intravitreal injections in study FVF2598g or this extension study.</description>
        </group>
        <group group_id="P4">
          <title>Ranibizumab Treated PDT XO</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated PDT XO includes participants who received sham intravitreal injections in combination with photodynamic therapy in study FVF2428g or study FVF2587g before crossing over to receive ranibizumab intravitreal injections in study FVF2428g, study FVF2587g or this study.</description>
        </group>
        <group group_id="P5">
          <title>Ranibizumab Untreated Group</title>
          <description>In this extension study participants did not receive Ranibizumab. Participants in this group were enrolled in one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) FVF2598g (NCT0056823) but did not receive Ranibizumab intravitreal injections in that study or in this extension study (FVF3426g).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="526"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="116"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Ranibizumab in Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="113"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="476"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Verteporfin photodynamic therapy in eye</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects condition mandated intervention</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RanibizumabTreated Initial Mono</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Participants in this group received ranibizumab 0.5 mg monotherapy, that is, ranibizumab alone in study FVF2598g or ranibizumab in combination with sham photodynamic therapy (PDT) in study FVF2587g.</description>
        </group>
        <group group_id="B2">
          <title>RanibizumabTreated Initial + PDT</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. This group includes participants who received ranibizumab 0.5 mg intravitreal injections in combination with photodynamic therapy in Study FVF2428g.</description>
        </group>
        <group group_id="B3">
          <title>RanibizumabTreated Sham XO</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated Sham Crossover (XO) includes participants who received sham intravitreal injections before crossing over to receive ranibizumab 0.5mg intravitreal injections in previous study FVF2598g or in this extension study.</description>
        </group>
        <group group_id="B4">
          <title>Ranibizumab Treated PDT XO</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated PDT XO includes participants who received sham intravitreal injections in combination with photodynamic therapy in study FVF2428g or study FVF2587g before crossing over to receive ranibizumab 0.5 mg intravitreal injections in previous studies FVF2428g, study FVF2587g or this extension study.</description>
        </group>
        <group group_id="B5">
          <title>Ranibizumab Untreated Group</title>
          <description>In this extension study participants did not receive Ranibizumab. Participants in this group were previously enrolled in one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594), FVF2598g (NCT0056823) but did not receive treatment with Ranibizumab in that study or in this extension study (FVF3426g).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="526"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="116"/>
            <count group_id="B4" value="74"/>
            <count group_id="B5" value="63"/>
            <count group_id="B6" value="853"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50 to &lt; 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt; 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 to &lt; 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="499"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Ocular Adverse Events</title>
        <description>Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye).
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.</description>
        <time_frame>36 months</time_frame>
        <population>All enrolled participants treated with Ranibizumab in this extension study or in one of the previous studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Treated Initial Mono</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Participants in this group previously received ranibizumab monotherapy (Mono), that is, ranibizumab 0.5 mg intravitreal injection alone in previous study FVF2598g or ranibizumab 0.5 mg intravitreal injection in combination with sham photodynamic therapy (PDT) in previous study FVF2587g.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Treated Initial + PDT</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. This group includes participants who received ranibizumab 0.5 mg intravitreal injection in combination with photodynamic therapy in previous Study FVF2428g.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Treated Sham XO</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated Sham Crossover (XO) includes participants who received sham intravitreal injections before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2598g or this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab Treated PDT XO</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated PDT XO includes participants who received sham intravitreal injections in combination with photodynamic therapy in previous study FVF2428g or previous study FVF2587g before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2428g, previous study FVF2587g or this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ocular Adverse Events</title>
          <description>Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye).
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.</description>
          <population>All enrolled participants treated with Ranibizumab in this extension study or in one of the previous studies.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event in study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events in study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events led to discontinuation, study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endophthalmitis in study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular inflammation in study eye, total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Intraocular inflammation in study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any adverse event in fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events in fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events led to discontinuation, fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endophthalmitis in fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular inflammation in fellow eye, total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious intraocular inflammation in fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non-ocular Adverse Events</title>
        <description>Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Additional information about adverse events can be found in the adverse events section.</description>
        <time_frame>36 months</time_frame>
        <population>Enrolled participants treated with Ranibizumab in this extension study or in one of the previous studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Treated Initial Mono</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Participants in this group previously received ranibizumab monotherapy (Mono), that is, ranibizumab 0.5 mg intravitreal injection alone in previous study FVF2598g or ranibizumab 0.5 mg intravitreal injection in combination with sham photodynamic therapy (PDT) in previous study FVF2587g.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Treated Initial + PDT</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. This group includes participants who received ranibizumab 0.5 mg intravitreal injection in combination with photodynamic therapy in previous Study FVF2428g.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Treated Sham XO</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated Sham Crossover (XO) includes participants who received sham intravitreal injections before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2598g or this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab Treated PDT XO</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated PDT XO includes participants who received sham intravitreal injections in combination with photodynamic therapy in previous study FVF2428g or previous study FVF2587g before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2428g, previous study FVF2587g or this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-ocular Adverse Events</title>
          <description>Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Additional information about adverse events can be found in the adverse events section.</description>
          <population>Enrolled participants treated with Ranibizumab in this extension study or in one of the previous studies.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any non ocular adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious non ocular adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non ocular adverse events led to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters</title>
        <description>Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
        <time_frame>Extension study baseline, Months 3, 6, 9, 12, 15, 18, 21 and 24</time_frame>
        <population>Enrolled participants. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Initial Group</title>
            <description>In this extension study participants received Ranibizumab injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group were initially enrolled and received treatment with Ranibizumab in one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823).</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Crossover Group</title>
            <description>In this extension study participants received Ranibizumab injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group were enrolled but did not initially receive Ranibizumab in Study FVF2428g (NCT00056823), Study FVF2587g (NCT00061594) or Study FVF2598g (NCT00056836) and then crossed over to receive Ranibizumab either in that initial study or this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Untreated Group</title>
            <description>In this extension study participants did not receive Ranibizumab. Participants in this group were enrolled in one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823) but did not receive treatment with Ranibizumab in that study or this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters</title>
          <description>Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
          <population>Enrolled participants. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="600"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="853"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Month 3 (n=284, 84, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="8.9"/>
                    <measurement group_id="O2" value="-2.9" spread="11.0"/>
                    <measurement group_id="O3" value="0.1" spread="6.6"/>
                    <measurement group_id="O4" value="-2.7" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 6 (n=519, 149, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="8.8"/>
                    <measurement group_id="O2" value="-1.6" spread="10.5"/>
                    <measurement group_id="O3" value="0.3" spread="7.0"/>
                    <measurement group_id="O4" value="-2.8" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 9 (n=490, 149, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="10.8"/>
                    <measurement group_id="O2" value="-1.7" spread="11.3"/>
                    <measurement group_id="O3" value="-2.2" spread="7.5"/>
                    <measurement group_id="O4" value="-3.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=481, 142, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="11.1"/>
                    <measurement group_id="O2" value="-2.3" spread="11.5"/>
                    <measurement group_id="O3" value="-3.2" spread="8.0"/>
                    <measurement group_id="O4" value="-4.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 15 (n=447, 138, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="10.8"/>
                    <measurement group_id="O2" value="-2.2" spread="12.4"/>
                    <measurement group_id="O3" value="-3.0" spread="8.9"/>
                    <measurement group_id="O4" value="-4.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 18 (n=420, 135, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="11.9"/>
                    <measurement group_id="O2" value="-2.0" spread="12.5"/>
                    <measurement group_id="O3" value="-4.4" spread="9.5"/>
                    <measurement group_id="O4" value="-5.3" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 21 (n=405, 129, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="13.0"/>
                    <measurement group_id="O2" value="-2.1" spread="13.3"/>
                    <measurement group_id="O3" value="-3.5" spread="10.8"/>
                    <measurement group_id="O4" value="-6.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=388, 127, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="13.0"/>
                    <measurement group_id="O2" value="-2.0" spread="13.5"/>
                    <measurement group_id="O3" value="-2.9" spread="8.5"/>
                    <measurement group_id="O4" value="-6.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters</title>
        <description>Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
        <time_frame>Extension study baseline, Months 12 and 24</time_frame>
        <population>Enrolled participants. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Initial Group</title>
            <description>In this extension study participants received Ranibizumab injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group were initially enrolled and received treatment with Ranibizumab in one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823).</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Crossover Group</title>
            <description>In this extension study participants received Ranibizumab injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group were enrolled but did not initially receive Ranibizumab in Study FVF2428g (NCT00056823), Study FVF2587g (NCT00061594) or Study FVF2598g (NCT00056836) and then crossed over to receive Ranibizumab either in the initial study or this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Untreated Group</title>
            <description>In this extension study participants did not receive Ranibizumab. Participants in this group were enrolled in one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823) but did not receive treatment with Ranibizumab in that study or this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters</title>
          <description>Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
          <population>Enrolled participants. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="600"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="853"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Month 12 (n=446,133,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="11.8"/>
                    <measurement group_id="O2" value="-1.3" spread="11.8"/>
                    <measurement group_id="O3" value="-3.2" spread="7.2"/>
                    <measurement group_id="O4" value="-4.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=352,122,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="12.3"/>
                    <measurement group_id="O2" value="-0.8" spread="13.0"/>
                    <measurement group_id="O3" value="-3.1" spread="8.2"/>
                    <measurement group_id="O4" value="-5.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24</title>
        <description>Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>Population included all enrolled participants treated with Ranibizumab in the extension study or in one of the initial studies. The number of participants for whom data was available at Month 12 and Month 24 are represented by &quot;n&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Treated Initial Mono</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Participants in this group previously received ranibizumab monotherapy (Mono), that is, ranibizumab 0.5 mg intravitreal injection alone in previous study FVF2598g or ranibizumab 0.5 mg intravitreal injection in combination with sham photodynamic therapy (PDT) in previous study FVF2587g.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Treated Initial + PDT</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. This group includes participants who received ranibizumab 0.5 mg intravitreal injection in combination with photodynamic therapy in previous Study FVF2428g.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Treated Sham XO</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated Sham Crossover (XO) includes participants who received sham intravitreal injections before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2598g or this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab Treated PDT XO</title>
            <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated PDT XO includes participants who received sham intravitreal injections in combination with photodynamic therapy in previous study FVF2428g or previous study FVF2587g before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2428g, previous study FVF2587g or this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24</title>
          <description>Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.</description>
          <population>Population included all enrolled participants treated with Ranibizumab in the extension study or in one of the initial studies. The number of participants for whom data was available at Month 12 and Month 24 are represented by &quot;n&quot;</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n=393,55,72,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=316,45,78,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The summary includes adverse events that occurred from enrollment in this extension study through 36 months (+/- 7 days).</time_frame>
      <desc>Safety Population includes all participants who received at least one dose of study drug in one of the initial studies or this extension study. As per the protocol participants who did not receive study drug were excluded from the analyses.
Only adverse events that occurred during this extension study are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab Treated Initial Mono</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Participants in this group previously received ranibizumab monotherapy (Mono), that is, ranibizumab 0.5 mg intravitreal injection alone in previous study FVF2598g or ranibizumab 0.5 mg intravitreal injection in combination with sham photodynamic therapy (PDT) in previous study FVF2587g.</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab Treated Initial + PDT</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. This group includes participants who received ranibizumab 0.5 mg intravitreal injection in combination with photodynamic therapy in previous Study FVF2428g.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab Treated Sham XO</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated Sham Crossover (XO) includes participants who received sham intravitreal injections before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2428g or this extension study.</description>
        </group>
        <group group_id="E4">
          <title>Ranibizumab Treated PDT XO</title>
          <description>In this extension study participants received Ranibizumab intravitreal injection 0.5 mg in the study eye given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. Ranibizumab Treated PDT XO includes participants who received sham intravitreal injections in combination with photodynamic therapy in previous study FVF2428g or previous study FVF2587g before crossing over to receive ranibizumab 0.5 mg intravitreal injection in previous study FVF2428g, previous study FVF2587g or this extension study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="213" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CARDIOâˆ’RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOPARATHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CHOROIDAL NEOVASCULARISATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>OPTIC ISCHAEMIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>POSTERIOR CAPSULE OPACIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ANGLE CLOSURE GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PAPILLOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL PIGMENT EPITHELIAL TEAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SUBRETINAL FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>UVEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VITRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ABDOMINAL COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COLONIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COLONIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PHARYNGOESOPHAGEAL DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>IDIOSYNCRATIC DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>KERATITIS HERPETIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VIRAL MYOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PUBIC RAMI FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ARTERIAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MEDICATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>STRESS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>THERAPEUTIC AGENT TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTRAOCULAR PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SACROILIITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>NONâˆ’HODGKINâ€™S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>OVARIAN EPITHELIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BRAIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BRAIN STEM INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CEREBELLAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COMPLEX REGIONAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMERâ€™S TYPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SPONDYLITIC MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>THROMBOTIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PELVIC PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="491" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CHOROIDAL NEOVASCULARISATION</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MYODESOPSIA</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DETACHMENT OF RETINAL PIGMENT EPITHELIUM</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>EYE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>POSTERIOR CAPSULE OPACIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY SENSATION IN EYES</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>RETINAL DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PHOTOPSIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SUBMACULAR FLUID</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTRAOCULAR PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Genentech</name_or_title>
      <organization>Genentech</organization>
      <email>ctg-post-d@gene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

